Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses

被引:29
作者
Bilsland, Alan E.
Merron, Andrew
Vassaux, Georges
Keith, W. Nicol
机构
[1] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland
[2] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Mol Oncol, London, England
[3] Barts & London Queen Marys Sch Med & Dent, Canc Res UK, Ctr Clin, London, England
关键词
D O I
10.1158/0008-5472.CAN-06-3000
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The telomerase RNA (hTR) and reverse transcriptase (hTERT) promoters are active in most cancer cells, but not in normal cells, and are useful for transcriptional targeting in gene therapy models. Telomerase-specific conditionally replicating adenoviruses (CRAB) are attractive vectors because they should selectively lyse tumor cells. Here, we compare CRAds, in which either the hTR or hTERT promoter controls expression of the adenovirus E1A gene. In replication-defective reporter adenoviruses, the hTR promoter was up to 57-fold stronger in cancer cells than normal cells and up to 49-fold stronger than hTERT. In normal cells, hTERT promoter activity was essentially absent. Doses of telomerase-specific CRAds between 1.8 and 28 infectious units per cell efficiently killed cancer cells, but normal cells required higher doses. However, CRAB DNA replication and E1A expression were detected in both cancer and normal cells. Overall, tumor specificity of the CRAds was limited compared with non-replicating vectors. Surprisingly, both CRAds expressed similar E1A levels and functional behavior, despite known differentials between hTR and hTERT promoter activities, suggesting that the promoters are deregulated. Rapid amplification of cDNA ends analysis of hTR-/hTERT-E1A transcripts ruled out cryptic transcription from the vector backbone. Blocking E1A translation partially restored the hTR-/hTERT-E1A mRNA differential, evidencing feedback regulation by E1A.
引用
收藏
页码:1299 / 1307
页数:9
相关论文
共 48 条
[1]
Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells [J].
Abdul-Ghani, R ;
Ohana, P ;
Matouk, I ;
Ayesh, S ;
Ayesh, B ;
Laster, M ;
Bibi, O ;
Giladi, H ;
Molnar-Kimber, K ;
Sughayer, MA ;
de Groot, N ;
Hochberg, A .
MOLECULAR THERAPY, 2000, 2 (06) :539-544
[2]
Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA [J].
Autexier, C ;
Pruzan, R ;
Funk, WD ;
Greider, CW .
EMBO JOURNAL, 1996, 15 (21) :5928-5935
[3]
Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions [J].
Bachand, F ;
Autexier, C .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1888-1897
[4]
Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3 [J].
Bilsland, AE ;
Stevenson, K ;
Atkinson, S ;
Kolch, W ;
Keith, WN .
CANCER RESEARCH, 2006, 66 (03) :1363-1370
[5]
Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy [J].
Bilsland, AE ;
Fletcher-Monaghan, A ;
Keith, WN .
NEOPLASIA, 2005, 7 (11) :1020-1029
[6]
Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase [J].
Bilsland, AE ;
Anderson, CJ ;
Fletcher-Monaghan, AJ ;
McGregor, F ;
Evans, TRJ ;
Ganly, I ;
Knox, RJ ;
Plumb, JA ;
Keith, WN .
ONCOGENE, 2003, 22 (03) :370-380
[7]
An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells [J].
Bortolanza, S ;
Qian, C ;
Kramer, MG ;
Gomar, C ;
Prieto, J ;
Farinati, F ;
Hernandez-Alcoceba, R .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2005, 83 (09) :736-747
[8]
An efficient targeted radiotherapy/gene therapy strategy utilising human tetomerase promoters and radioastatine and harnessing radiation-mediated bystander effects [J].
Boyd, M ;
Mairs, RJ ;
Keith, WN ;
Ross, SC ;
Welsh, P ;
Akabani, G ;
Owens, J ;
Vaidyanathan, G ;
Carruthers, R ;
Dorrens, J ;
Zalutsky, MR .
JOURNAL OF GENE MEDICINE, 2004, 6 (08) :937-947
[9]
Expression of telomerase RNA in oesophageal and oral cancer [J].
Downey, MG ;
Going, JJ ;
Stuart, RC ;
Keith, WN .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2001, 30 (10) :577-581
[10]
Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors [J].
Dufès, C ;
Keith, WN ;
Bilsland, A ;
Proutski, I ;
Uchegbu, JF ;
Schätzlein, AG .
CANCER RESEARCH, 2005, 65 (18) :8079-8084